Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 203-268-9 | CAS number: 105-08-8
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Developmental toxicity / teratogenicity
Administrative data
- Endpoint:
- developmental toxicity
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- guideline study
Data source
Reference
- Reference Type:
- study report
- Title:
- Unnamed
- Year:
- 2 013
Materials and methods
Test guidelineopen allclose all
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 414 (Prenatal Developmental Toxicity Study)
- Deviations:
- no
- Qualifier:
- according to guideline
- Guideline:
- EPA OPPTS 870.3700 (Prenatal Developmental Toxicity Study)
- Qualifier:
- according to guideline
- Guideline:
- other: Japan 12 NohSan No 8147, (24 November 2000)
- GLP compliance:
- yes (incl. QA statement)
- Limit test:
- no
Test material
- Reference substance name:
- Cyclohex-1,4-ylenedimethanol
- EC Number:
- 203-268-9
- EC Name:
- Cyclohex-1,4-ylenedimethanol
- Cas Number:
- 105-08-8
- Molecular formula:
- C8H16O2
- IUPAC Name:
- cyclohexane-1,4-diyldimethanol
- Test material form:
- other: Off white solid
- Details on test material:
Batch number :
Label : 1, 4-cyclohexanedimethanol Batch TP12008082
Storage conditions : Ambient, in the dark
- Name of test material (as cited in study report):1, 4-cyclohexane dimethanol
- Substance type: solid, easily melted
- Analytical purity: 100.0%
- Lot/batch No.:TP12008082
- Expiration date of the lot/batch: Not determined
- Storage condition of test material: Ambient, in the dark
- Other: Test item was received as an off white solid and warmed to produce a clear colourless liquid prior to use. It remained a clear colourless liquid after heating.
Constituent 1
- Specific details on test material used for the study:
- Sponsor’s Identification : 1, 4-cyclohexane dimethanol
Description : Off white solid/clear colourless liquid*
Chemical name : cyclohex-1, 4-ylenedimethanol
CAS number : 105-08-8
Purity : 100%
Batch number : TP12008082
Label : 1, 4-cyclohexanedimethanol
Batch TP12008082
Date received : 16 April 2012
Storage conditions : Ambient, in the dark
Expiry date : not supplied
Test animals
- Species:
- rat
- Strain:
- Crj: CD(SD)
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS
- Source: Charles River (UK) Limited, Margate, Kent
- Weight at study initiation: 216-299
- Housing: Individually in solid-floor polypropylene cages with stainless steel lid
- Diet (e.g. ad libitum):Yes, Rodent 2018C Teklad Global Certified Diet, Harlan UK, Oxon, UK
- Water (e.g. ad libitum):Yes
- Acclimation period: No
ENVIRONMENTAL CONDITIONS
- Temperature (°C): 22 +/- 3
- Humidity (%): 50 +/- 20
- Air changes (per hr): ~15
- Photoperiod (hrs dark / hrs light): 12/12
Administration / exposure
- Route of administration:
- oral: gavage
- Vehicle:
- water
- Details on exposure:
- Oral gavage was chosen as the route of exposure
Dose levels were chosen in collaboration with the Sponsor based on available toxicity data including a preliminary rat pre-natal development toxicity study. In the preliminary study, there were no effects observed for the pregnant females and developing offspring at 1000 mg/kg bw/day that was considered to preclude this dosage from use as the high dosage in this main study. Dosing formulations using distilled water were successfully used on the preliminary study, therefore distilled water as a vehicle and a treatment volume of 5 ml/kg bw/day will be employed on this main study.
As no increase in pre-implantation loss had been observed in the rat preliminary prenatal development study dosing on this
main study commenced on Day 3 of gestation. The test item was therefore administered daily, from Day 3 to 19 of gestation (the day prior to necropsy), by gavage. Control animals were treated in an identical manner with the vehicle only. The volume of test and control item administered to each animal was based on the most recently recorded individual scheduled body weight and adjusted accordingly. - Analytical verification of doses or concentrations:
- yes
- Details on analytical verification of doses or concentrations:
The concentration of 1,4–cyclohexane dimethanol in the test item formulations was determined by gas chromatography (GC) using an external standard technique. The test item formulations were diluted with acetonitrile to give a final, theoretical test item concentration of approximately 0.05 mg/ml. Standard solutions of test item were prepared in acetonitrile at a nominal concentration of 0.05 mg/ml. The standard and sample solutions were analysed by GC using the following conditions:
GC system : Agilent Technologies 5890, incorporating autosampler and workstation
Column : DB-5 (30 m x 0.53 mm id x 5 μm film)
Oven temperature program : initial 50 ºC for 1 mins rate 10 ºC/min final 260 ºC for 5 mins
Injection temperature : 250 ºC
FID temperature: 250 ºC
Injection volume : 1 μl
Retention time : ~ 13 mins
The test item formulations were assessed visually for homogeneity. The stability of the test item in the vehicle matrix during storage at approximately +4 °C
in the dark was confirmed to be at least fourteen days. Results from analysis of dosing formulations used during the study were 99-105% of
nominal concentration confirming the accuracy of the formulation procedure.- Details on mating procedure:
- Animals were purchased already mated
- Duration of treatment / exposure:
- Days 3-19 of gestation
- Frequency of treatment:
- Once/day
- Duration of test:
- Aprroximately 17 days
Doses / concentrationsopen allclose all
- Dose / conc.:
- 100 mg/kg bw/day
- Dose / conc.:
- 300 mg/kg bw/day
- Dose / conc.:
- 1 000 mg/kg bw/day
- No. of animals per sex per dose:
- 24
- Control animals:
- yes, concurrent vehicle
- Details on study design:
- Dose levels were chosen in collaboration with the Sponsor based on available toxicity data including a preliminary rat pre-natal development toxicity study. In the preliminary study, there were no effects observed for the pregnant females and developing offspring at 1000 mg/kg bw/day that was considered to preclude this dosage from use as the high dosage in this main study.
Examinations
- Maternal examinations:
- CAGE SIDE OBSERVATIONS: Yes
- Time schedule: Once daily, Additionally, during the dosing period observations were recorded immediately before and soon after dosing and one hour post dosing. An additional observation was also performed five hours after dosing during the normal working week (excluding weekend and
public holidays).
DETAILED CLINICAL OBSERVATIONS: Yes / No / No data
- Time schedule:
BODY WEIGHT: Yes
- Time schedule for examinations: Individual body weights were recorded on Day 3 (before the start of treatment) and on Days 4, 5, 8, 11, 14 and 17 of gestation. Body weights were also recorded for animals at terminal kill (Day 20).
FOOD CONSUMPTION AND COMPOUND INTAKE (if feeding study): Yes
- Food consumption for each animal determined and mean daily diet consumption calculated as g food/kg body weight/day: Yes
- Compound intake calculated as time-weighted averages from the consumption and body weight gain data: No
- Food consumption was recorded for each individual animal for the Days 3 to 5, 5 to 8, 8 to 11, 11 to 14, 14 to 17 and 17 to 20.
WATER CONSUMPTION AND COMPOUND INTAKE (if drinking water study): Yes / No / No data
- Time schedule for examinations:
POST-MORTEM EXAMINATIONS: Yes
- Sacrifice: All animals were killed by carbon dioxide asphyxiation followed by cervical dislocation on Day 20 of gestation.
- Organs examined: All animals were subjected to a full external and internal examination and any macroscopic abnormalities were recorded. The
adrenals were removed from all animals, dissected free from fat and weighed before fixation in 10% buffered formulin.
OTHER: - Ovaries and uterine content:
- The ovaries and uteri of pregnant females were removed, examined and the folllowing data recorded:
i) Number of corpora lutea
ii) Number, position and type of intrauterine implantation
iii) Foetal sex
iv) External foetal appearance
v) Foetal weight
vi) Placental weight
vii) Gravid uterus weight
The uteri of any apparently non-pregnant females were immersed in 10% ammonium sulphide to reveal evidence of implantation. - Fetal examinations:
- The foetuses were killed by subcutaneous injection of sodium pentobarbitone. Foetuses from each litter were divided into two groups and examined for skeletal alterations and soft tissue alterations. Alternate foetuses were identified using an indelible marker and placed in Bouin’s fixative. Foetuses were transferred to 70% industrial methylated spirits (IMS) in distilled water and examined for visceral anomalies under a low power binocular
microscope. The remaining foetuses were identified using colour coded wires and placed in 70% IMS in distilled water. The foetuses were eviscerated, processed and the skeletons stained with alizarin red. The foetuses were examined for skeletal development and anomalies. Following examination
foetuses that were examined for skeletal development were placed in 100% glycerol. - Statistics:
- The following parameters were analysed statistically, where appropriate, using the test methods outlined below:
Female body weights and body weight change, food consumption, adrenal weights and gravid uterus weight: Initially, homogeneity of the data was assessed using Levene’s Test. Where Levene’s Test is found to be non-significant (P>0.05) parametric assessment of the data was performed;
analysis of variance (ANOVA) followed by (if significant (p,<0.05)) pair-wise comparisons using Dunnett’s test. Where Levene’s Test was
significant, non-parametric assessments of the data was applied; Kruskal-Wallis test followed by (if significant (p<0.05)) Mann-Whitney U test. All caesarean necropsy parameters and foetal parameters, including skeletal and visceral findings: Kruskal-Wallis non-parametric analysis of
variance; and a subsequent pairwise analysis of control values against treated values using the Mann-Whitney ‘U’ test, where significance was seen. - Indices:
- All data was summarised in tabular form, including reproductive incides. Where appropriate group mean values were calculated to includes data from all females with live foetuses on Day 20 of gestation. For terminal body weight and overall body weightgain during treatment this included adjustment for the contribution of the gravid uterus. For adrenal weights both absolute and body weight-relative values are presented The litter was considered to represent the standard unit of assessment, therefore individual litter values including mean foetal weights, mean placental weight, pre- and post implantation losses, sex ratio and foetal visceral and skeletal findings were first calculated for each litter and then group values calculated from these individual litter values.
Pre and Post Implantation Loss
Percentage pre-implantation loss was calculated as:
[(number of corpora lutea - number of implantations) / number of corpora lutea] x 100
Percentage post-implantation loss was calculated as:
[(number of implantations - number of live foetuses) / number of implantations] x 100
Sex Ratio
Sex ratio was calculated for each litter using the following formula:
% male foetuses (sex ratio) = (Number of male foetuses/ Total number of foetuses) x 100 - Historical control data:
- Historical control data on placental weights from 6 studies was supplied. The control values inclueded the previous 3 studies, the present study and the subsequent 2. The average weights for the control placentals was 0.53 grams with a range of (0.51 - 0.57).
Results and discussion
Results: maternal animals
General toxicity (maternal animals)
- Clinical signs:
- no effects observed
- Description (incidence and severity):
- There were no clinical signs observed that were considered to be associated with treatment at 100, 300 or 1000 mg/kg bw/day. At 1000 mg/kg bw/day, one female showed chromodacryorrhoea or staining around the eyes throughout most of the study from Day 11 of gestation. In isolation this finding was considered incidental and unrelated to treatment.
- Dermal irritation (if dermal study):
- not examined
- Mortality:
- no mortality observed
- Body weight and weight changes:
- no effects observed
- Description (incidence and severity):
- Body weights and body weight gain, including values adjusted for the contribution of the gravid uterus, were unaffected by treatment at 100, 300 and 1000 mg/kg bw/day
- Food consumption and compound intake (if feeding study):
- no effects observed
- Description (incidence and severity):
- Food consumption was unaffected by treatment at 100, 300 and 1000 mg/kg bw/day.
- Food efficiency:
- no effects observed
- Water consumption and compound intake (if drinking water study):
- not examined
- Ophthalmological findings:
- not examined
- Haematological findings:
- not examined
- Clinical biochemistry findings:
- not examined
- Urinalysis findings:
- not examined
- Behaviour (functional findings):
- not examined
- Immunological findings:
- not examined
- Organ weight findings including organ / body weight ratios:
- not examined
- Description (incidence and severity):
- At 1000 mg/kg bw/day higher body weight-relative adrenals weights attained statistical significance when compared to control; no statistically significant differences from control were apparent for absolute adrenal weights.
There was no obvious effect of treatment on absolute or body weight relative adrenal weights at 100 or 300 mg/kg bw/day. - Gross pathological findings:
- no effects observed
- Description (incidence and severity):
- No macroscopic abnormalities were detected for adult animals at Day 20 of gestation
- Neuropathological findings:
- not examined
- Histopathological findings: non-neoplastic:
- not examined
- Histopathological findings: neoplastic:
- not examined
- Other effects:
- not specified
Maternal developmental toxicity
- Number of abortions:
- no effects observed
- Pre- and post-implantation loss:
- no effects observed
- Description (incidence and severity):
- There was no effect of treatment on in-utero offspring survival, as assessed by the mean numbers of early or late resorptions, live litter size and pre and post-implantation losses
- Total litter losses by resorption:
- no effects observed
- Description (incidence and severity):
- There was no effect of treatment on in-utero offspring survival, as assessed by the mean numbers of early or late resorptions, live litter size and pre and post-implantation losses
- Early or late resorptions:
- no effects observed
- Description (incidence and severity):
- There was no effect of treatment on in-utero offspring survival, as assessed by the mean numbers of early or late resorptions, live litter size and pre and post-implantation losses
- Dead fetuses:
- no effects observed
- Description (incidence and severity):
- There was no effect of treatment on in-utero offspring survival, as assessed by the mean numbers of early or late resorptions, live litter size and pre and post-implantation losses
- Changes in pregnancy duration:
- not examined
- Description (incidence and severity):
- Not valid in an OECD 414
- Changes in number of pregnant:
- no effects observed
- Description (incidence and severity):
- There was no effect of treatment on in-utero offspring survival, as assessed by the mean numbers of early or late resorptions, live litter size and pre and post-implantation losses
- Other effects:
- not specified
- Details on maternal toxic effects:
- Maternal toxic effects:no effects
Details on maternal toxic effects:
THere were no mortalities
There were no clinical signs of toxicity
There was no effects on body weight or weight gain
There was no effect on food consumption
There were no post mortem macroscopic abnormalities
Effect levels (maternal animals)
- Dose descriptor:
- NOAEL
- Effect level:
- 1 000 mg/kg bw/day (actual dose received)
- Based on:
- test mat.
- Basis for effect level:
- body weight and weight gain
- clinical signs
- mortality
- Remarks on result:
- not determinable due to absence of adverse toxic effects
- Remarks:
- NOAEL was high dose
Maternal abnormalities
- Abnormalities:
- no effects observed
Results (fetuses)
- Fetal body weight changes:
- effects observed, non-treatment-related
- Description (incidence and severity):
- There was no effect of treatment on mean placental foetal or litter weight at 100, 300 or 1000 mg/kg bw/day. At 1000 mg/kg bw/day mean placental weight was slightly higher than control with differences attaining statistical significance. However, the mean value at this dosage was within the control range of four contemporary pre-natal studies performed within these laboratories, while the mean control value was slightly lower than this control range. It is considered that the statistical differences in placental weights observed at 1000 mg/kg bw/day most probably reflect slightly lower values for control litters and therefore are a result of normal biological variation, unrelated to treatment.
- Reduction in number of live offspring:
- no effects observed
- Changes in sex ratio:
- no effects observed
- Changes in litter size and weights:
- no effects observed
- Changes in postnatal survival:
- not specified
- Description (incidence and severity):
- not relevant for an OECD 414
- External malformations:
- no effects observed
- Description (incidence and severity):
- Neither the type, incidence or distribution of findings observed externally at necropsy examination and subsequently during detailed visceral and skeletal assessment indicated any effect of treatment on foetal development.
- Skeletal malformations:
- no effects observed
- Description (incidence and severity):
- Neither the type, incidence or distribution of findings observed externally at necropsy examination and subsequently during detailed visceral and skeletal assessment indicated any effect of treatment on foetal development.
- Visceral malformations:
- no effects observed
- Description (incidence and severity):
- Neither the type, incidence or distribution of findings observed externally at necropsy examination and subsequently during detailed visceral and skeletal assessment indicated any effect of treatment on foetal development.
- Other effects:
- not specified
- Details on embryotoxic / teratogenic effects:
- Embryotoxic / teratogenic effects:no effects
Details on embryotoxic / teratogenic effects:
THere was no effects on foetal or litter weight No external or skeletal effects were observed in the developing foetus All foetal parameters were similar to controls The developmental NOEL was 1000 mg/kg
Effect levels (fetuses)
- Dose descriptor:
- NOAEL
- Effect level:
- 1 000 mg/kg bw/day
- Based on:
- test mat.
- Sex:
- male/female
- Basis for effect level:
- external malformations
- skeletal malformations
- visceral malformations
- Remarks on result:
- not determinable due to absence of adverse toxic effects
Fetal abnormalities
- Abnormalities:
- no effects observed
Overall developmental toxicity
- Developmental effects observed:
- no
Any other information on results incl. tables
Relative adrenal weights were significantly increased in the 1000 mg/kg/day dose group compared to controls. There was no change in the absolute adrenal weight, nor was there a significant change in the absolute or relative adrenal weights in the 100 or 300 mg/kg/day groups. There were no morphologic changes to the adrenals, and no clinical signs found. The increase in adrenal weights was not considered to be an adverse event.
At 1000 mg/kg bw/day mean placental weight was slightly higher than control with differences attaining statistical significance. However, the mean value at this dosage was within the control range of four contemporary pre-natal studies performed within these laboratories, while the mean control value was slightly lower than this control range. It is considered that the statistical differences in placental weights observed at 1000 mg/kg bw/day most probably reflect slightly lower values for control litters and therefore are a result of normal biological variation, unrelated to treatment.
Summary table are attached as a single .PDF in the "attached full study report" section
Applicant's summary and conclusion
- Conclusions:
- The oral administration of 1,4-cyclohexane dimethanol to pregnant rats at 1000 mg/kg bw/day was well tolerated with only an increase in body weight-relative adrenals weights preventing this dosage from being considered the ‘No Observed Effect Level’ (NOEL) for the pregnant female. This dosage represents a clear No Observed Adverse Effect Level (NOAEL) for the pregnant female with the NOEL being 300 mg/kg bw/day. The NOEL for the survival, growth and morphological development the conceptus was considered to be 1000 mg/kg bw/day.
- Executive summary:
The study was was designed to investigate the effects of the test item on embryonic and foetal development following repeated administration by gavage to the pregnant female including the period of organogenesis.
The test item was administered by gavage to three groups each of twenty-four time mated Sprague-Dawley Crl:CD® (SD) IGS BR strain rats, between Days 3 and 19 of gestation at dose levels 100, 300, and 1000 mg/kg bw/day. A further group of twenty-four time mated females was exposed to the vehicle only (Distilled Water) to serve as a control over the same treatment period. Clinical signs, body weight change and food consumptions were monitored during the study. All surviving females were terminated on Day 20 of gestation and subjected to gross necropsy including adrenal organ weights and examination of the uterine contents. The number of corpora lutea, number, position and type of implantation, placental weights, foetal weight, sex and external and internal macroscopic appearance were recorded. Half of each litter were examined for skeletal development. The remaining half were examined viscerally.
There were no unscheduled deaths or clinical signs observed that were associated with treatment. There were no effects of treatment on body weight or body weight gain during gestation nor was there a chage in food intake. No macroscopic abnormalities were detected for adult animals at necropsy. At 1000 mg/kg bw/day there was a statistically significant increase in body weight-relative adrenals weights compared to control although there was no change in the absolute adrenal weights. There was no effect of treatment on numbers of early or late resorptions, live litter size or pre and post-implantation losses at any dose. There was no effect of treatment on mean placental, foetal or litter weight at 100, 300 or 1000 mg/kg bw/day, and external necropsy examination and subsequent detailed visceral and skeletal assessment did not indicate any effect of treatment on foetal development.
The oral administration of 1,4-cyclohexane dimethanol to pregnant rats at 1000 mg/kg bw/day was well tolerated with only an increase in body weight-relative adrenal weights preventing this dosage from being considered the ‘No Observed Effect
Level’ (NOEL) for the pregnant female. This dosage represents a clear No Observed Adverse Effect Level (NOAEL) for the pregnant female with the NOEL being 300 mg/kg bw/day. The NOEL for the survival, growth and morphological development the conceptus was considered to be 1000 mg/kg bw/day.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.